These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22595934)

  • 1. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension.
    Digiuni M; Manni G; Vetrugno M; Uva M; Milano G; Orzalesi N; Fogagnolo P; Centofanti M; Campos E; Rossetti L
    J Glaucoma; 2013 Dec; 22(9):707-12. PubMed ID: 22595934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.
    Allaire C; Dietrich A; Allmeier H; Grundmane I; Mazur-Piotrowska G; Neshev P; Kahle G
    Eur J Ophthalmol; 2012; 22(1):19-27. PubMed ID: 22167539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.
    Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V
    Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
    Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan
    Czumbel N; Acs T; Bator G; Halmosi A; Egorov EA; Maltsev DS
    BMC Ophthalmol; 2024 Jul; 24(1):313. PubMed ID: 39075412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
    Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
    J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.
    Jampel HD; Bacharach J; Sheu WP; Wohl LG; Solish AM; Christie W;
    Am J Ophthalmol; 2002 Dec; 134(6):863-71. PubMed ID: 12470755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension.
    Tsukamoto H; Mishima HK; Kitazawa Y; Araie M; Abe H; Negi A;
    J Glaucoma; 2002 Dec; 11(6):497-501. PubMed ID: 12483094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.